Von Willebrand factor in relation to coronary plaque characteristics and cardiovascular outcome

Summary

High von Willebrand factor (VWF) plasma levels are associated with an increased risk of coronary artery disease. It has been suggested that the increase of VWF levels is partly due to endothelial dysfunction and atherosclerosis. Our aim was to investigate the association between coronary plaque burden, the presence of high-risk coronary lesions as measured by intravascular ultrasound virtual histology (IVUS-VH) and VWF levels. In addition, we studied the association between VWF levels and one-year cardiovascular outcome. Between 2008 and 2011, IVUS-VH imaging of a non-culprit coronary artery was performed in 581 patients undergoing coronary angiography for acute coronary syndrome (ACS) (n= 318) or stable angina pectoris (SAP) (n= 263). Arterial blood was sampled prior to the coronary angiography. VWF antigen (VWF:Ag) levels were measured using ELISA (n= 577). Patients with ACS had significantly higher VWF:Ag levels than SAP patients (median 1.73 IU/ml [IQR 1.27–2.31] vs 1.26 IU/ml [0.93–1.63], p < 0.001). High coronary plaque burden was associated with higher VWF:Ag levels (β= 0.12, p=0.027) in SAP patients, but not in ACS patients. In ACS patients, VWF:Ag levels were associated with 1-year MACE (HR 4.14 per SD increase of lnVWF:Ag, 95 % CI 1.47–11.6), whereas in SAP patients VWF:Ag levels predicted 1-year all-cause death and hospitalisation for ACS (HR 7.07 95 % CI 1.40–35.6). In conclusion, coronary plaque burden was associated with VWF:Ag levels in SAP patients undergoing coronary angiography. In ACS and SAP patients, high VWF levels are predictive of adverse cardiovascular outcome and death during one-year follow-up.

Keywords

von Willebrand factor - acute myocardial infarction - atherosclerosis - cardiology

^* These authors contributed equally to this work.

• References

• 1 Ruggeri ZM. The role of von Willebrand factor in thrombus formation. Thromb Res 2007; 120 (Suppl. 01) S5-9.
• 2 Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?. Cardiovasc Res 1997; 34: 255-265.
• 3 Folsom AR, Wu KK, Shahar E. et al. Association of haemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Arteriosclerosis and thrombosis: a journal of vascular biology / American Heart Association 1993; 13: 1829-1836.
• 4 Willeit P, Thompson A, Aspelund T. et al. Haemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses. PloS one 2013; 8: e55175.
• 5 Rumley A, Lowe GD, Sweetnam PM. et al. Factor VIII von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br J Haematol 1999; 105: 110-116.
• 6 Tzoulaki I, Murray GD, Lee AJ. et al. Relative value of inflammatory, haemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007; 115: 2119-2127.
• 7 Folsom AR, Rosamond WD, Shahar E. et al. Prospective study of markers of haemostatic function with risk of ischaemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1999; 100: 736-742.
• 8 Sonneveld MA, de Maat MP, Leebeek FW. Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Rev 2014; 28: 167-178.
• 9 Fuster W, Bowie EJ, Lewis JC. et al. Resistance to arteriosclerosis in pigs with von Willebrand’s disease. Spontaneous and high cholesterol diet-induced arteriosclerosis. J Clin Invest 1978; 61: 722-730.
• 10 Fuster V, Fass DN, Kaye MP. et al. Arteriosclerosis in normal and von Willebrand pigs: long-term prospective study and aortic transplantation study. Circ Res 1982; 51: 587-593.
• 11 Methia N, Andre P, Denis CV. et al. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood 2001; 98: 1424-1428.
• 12 Bilora F, Zanon E, Casonato A. et al. Type IIb von Willebrand disease: role of qualitative defects in atherosclerosis and endothelial dysfunction. Clin Appl Thromb Haemost 2007; 13: 384-390.
• 13 Sramek A, Reiber JH, Gerrits WB. et al. Decreased coagulability has no clinically relevant effect on atherogenesis: observations in individuals with a hereditary bleeding tendency. Circulation 2001; 104: 762-767.
• 14 Federici AB, Mannucci PM, Fogato E. et al. Autopsy findings in three patients with von Willebrand disease type IIB and type III: presence of atherosclerotic lesions without occlusive arterial thrombi. Thromb Haemost 1993; 70: 758-761.
• 15 Sonneveld MA, van Dijk AC, van den Herik EG. et al. Relationship of Von Willebrand Factor with carotid artery and aortic arch calcification in ischaemic stroke patients. Atherosclerosis 2013; 230: 210-215.
• 16 Gogas BD, Farooq V, Serruys PW. et al. Assessment of coronary atherosclerosis by IVUS and IVUS-based imaging modalities: progression and regression studies, tissue composition and beyond. Int J Cardiovasc Imag 2011; 27: 225-237.
• 17 Garcia-Garcia HM, Gogas BD, Serruys PW. et al. IVUS-based imaging modalities for tissue characterisation: similarities and differences. Int J Cardiovasc Imag 2011; 27: 215-224.
• 18 Stone GW, Maehara A, Lansky AJ. et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011; 364: 226-235.
• 19 De Boer SPM, Cheng JM, Garcia-Garcia HM. et al. Relation of genetic profile and novel circulating biomarkers with coronary plaque phenotype as determined by intravascular ultrasound: Rationale and design of the ATHERORE-MO-IVUS study. EuroIntervention. 2013 Epub ahead of print.
• 20 Garcia-Garcia HM, Mintz GS, Lerman A. et al. Tissue characterisation using intravascular radiofrequency data analysis: recommendations for acquisition, analysis, interpretation and reporting. EuroIntervention 2009; 5: 177-189.
• 21 Rodriguez-Granillo GA, Garcia-Garcia HM, Mc Fadden EP. et al. In vivo intrav-ascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am Coll Cardiol 2005; 46: 2038-2042.
• 22 Cheng JM, Garcia-Garcia HM, de Boer SP. et al. In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study. Eur Heart J 2014; 35: 639-647.
• 23 Hamm CW, Bassand JP, Agewall S. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
• 24 Ruef J, Marz W, Winkelmann BR. Markers for endothelial dysfunction, but not markers for oxidative stress correlate with classical risk factors and the severity of coronary artery disease. (A subgroup analysis from the Ludwigshafen Risk and Cardiovascular Health Study). Scand Cardiovasc J 2006; 40: 274-279.
• 25 Pottinger BE, Read RC, Paleolog EM. et al. von Willebrand factor is an acute phase reactant in man. Thromb Res 1989; 53: 387-394.
• 26 Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006; 4: 1186-1193.
• 27 Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
• 28 Virmani R, Burke AP, Kolodgie FD. et al. Pathology of the thin-cap fibroathero-ma: a type of vulnerable plaque. J Interv Cardiol 2003; 16: 267-272.
• 29 McCarty OJ, Conley RB, Shentu W. et al. Molecular imaging of activated von Willebrand factor to detect high-risk atherosclerotic phenotype. JACC Cardiovasc Imaging 2010; 3: 947-55.
• 30 Ni M, Chen WQ, Zhang Y. Animal models and potential mechanisms of plaque destabilisation and disruption. Heart 2009; 95: 1393-1398.
• 31 Schwartz SM, Galis ZS, Rosenfeld ME. et al. Plaque rupture in humans and mice. Arterioscler Thromb Vasc Biol 2007; 27: 705-713.
• 32 Chen YC, Bui AV, Diesch J. et al. A novel mouse model of atherosclerotic plaque instability for drug testing and mechanistic/therapeutic discoveries using gene and microRNA expression profiling. Circ Res 2013; 113: 252-265.
• 33 Van der Donckt C, Van Herck JL, Schrijvers DM. et al. Elastin fragmentation in atherosclerotic mice leads to intraplaque neovascularisation, plaque rupture, myocardial infarction, stroke, and sudden death. Eur Heart J. 2014 Epub ahead of print.
• 34 Whincup PH, Danesh J, Walker M. et al. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2002; 23: 1764-1770.
• 35 Wannamethee SG, Whincup PH, Shaper AG. et al. Circulating inflammatory and haemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men. J Thromb Haemost 2009; 7: 1605-1611.
• 36 Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-355.
• 37 Bath PM, Blann A, Smith N. et al. Von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets 1998; 9: 155-159.
• 38 Catto AJ, Carter AM, Barrett JH. et al. von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality. Thromb Haemost 1997; 77: 1104-1108.
• 39 van Loon JE, Kavousi M, Leebeek FW. et al. Von willebrand factor plasma levels, genetic variations, and coronary heart disease in an older population. J Thromb Haemost 2012; 10: 1262-1269.
• 40 Moreno PR. Prediction of MACE after ACS: demographics and angiography versus imaging. JACC Cardiovasc Imaging 2013; 6: 1273-1276.
• 41 Garcia-Garcia HM, Costa MA, Serruys PW. Imaging of coronary atherosclerosis: intravascular ultrasound. Eur Heart J 2010; 31: 2456-2469